Title:LncRNA FTH1P3: A New Biomarker for Cancer-Related Therapeutic Development
Volume: 24
Issue: 5
Author(s): Maryam Darvish*
Affiliation:
- Department of Medical Biotechnology, School of Medicine, Arak University of Medical Sciences, Arak, Iran
Keywords:
lncRNA, FTH1P3, miRNA, cancer, proliferation, signaling pathway.
Abstract: Cancer is a persistent and urgent health problem that affects the entire world.
Not long ago, regulatory biomolecules referred to as long noncoding RNAs (lncRNAs)
might have value for their innate abundance and stability. These single-stranded RNAs
potentially interfere with several physiological and biochemical cellular processes
involved in many human pathological situations, particularly cancer diseases. Ferritin
heavy chain1 pseudogene 3 (FTH1P3), a lncRNA that is ubiquitously transcribed and
belongs to the ferritin heavy chain (FHC) family, represents a novel class of lncRNAs
primarily found in oral squamous cell carcinoma. Further research has shown that
FTH1P3 is involved in other malignancies such as uveal melanoma, glioma, esophageal
squamous cell carcinoma, non-small cell lung cancer, breast cancer, laryngeal squamous
cell carcinoma, and cervical cancer. Accordingly, FTH1P3 significantly enhances
cancer symptoms, including cell proliferation, invasion, metastasis, chemoresistance,
and inhibition of apoptosis through many specific mechanisms. Notably, the clinical data
significantly demonstrated the association of FTH1P3 overexpression with poor
prognosis and poor overall survival within the examined samples. Here, we summarize
all the research published to date (13 articles) on FTH1P3, focusing on the biological
function underlying the regulatory mechanism and its possible clinical relevance.
